CoChat

Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline

Fink, Howard A., Ishani, Areef, Taylor, Brent C., Greer, Nancy L., MacDonald, Roderick, Rossini, Dominic, Sadiq, Sameea, Lankireddy, Srilakshmi, Kane, Robert L., Wilt, Timothy J. · 2012 · Annals of Internal Medicine
Cited by 154

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Background: Screening and monitoring for chronic kidney disease (CKD) could lead to earlier interventions that improve clinical outcomes. Purpose: To summarize evidence about the benefits and harms of screening for and monitoring and treatment of CKD stages 1 to 3 in adults. Data Sources: MEDLINE (1985 through November 2011), reference lists, and expert suggestions. Study Selection: English-language, randomized, controlled trials that evaluated screening for or monitoring or treatment of CKD and that reported clinical outcomes. Data Extraction: Two reviewers assessed study characteristics and rated quality and strength of evidence. Data Synthesis: No trials evaluated screening or monitoring, and 110 evaluated treatments. Angiotensin-converting enzyme inhibitors (relative risk, 0.65 [95% CI, 0.49 to 0.88]) and angiotensin II–receptor blockers (relative risk, 0.77 [CI, 0.66 to 0.90]) reduced end-stage renal disease versus placebo, primarily in patients with diabetes who have macroalbuminuria. Angiotensin-converting enzyme inhibitors reduced mortality versus placebo (relative risk, 0.79 [CI, 0.66 to 0.96]) in patients with microalbuminuria and cardiovascular disease or high-risk diabetes. Statins and β-blockers reduced mortality and cardiovascular events versus placebo or control in patients with impaired estimated glomerular filtration rate and either hyperlipidemia or congestive heart failure, respectively. Risks for mortality, end-stage renal disease, or other clinical outcomes did not significantly differ between strict and usual blood pressure control. The strength of evidence was rated high for angiotensin II–receptor blockers and statins, moderate for angiotensin-converting enzyme inhibitors and β-blockers, and low for strict blood pressure control. Limitations: Evidence about outcomes was sometimes scant and derived from post hoc analyses of subgroups of patients enrolled in trials. Few trials reported or systematically collected information about adverse events. Selective reporting and publication bias were possible. Conclusion: The role of CKD screening or monitoring in improving clinical outcomes is uncertain. Evidence for CKD treatment benefit is strongest for angiotensin-converting enzyme inhibitors and angiotensin II–receptor blockers, and in patients with albuminuria combined with diabetes or cardiovascular disease. Primary Funding Source: Agency for Healthcare Research and Quality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-156-8-201204170-00008

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 25 references

Research works printed but not linked: 67

  1. National Kidney Foundation, 2002, Am J Kidney Dis, 39, S1
  2. 10.1038/ki.2010.550 · DOI · Paper page
  3. 10.1136/bmj.327.7414.557 · DOI · Paper page
  4. 10.1016/S0011-393X(99)90003-6 · DOI
  5. 10.1016/S0168-8227(01)00289-3 · DOI
  6. 10.7326/0003-4819-118-8-199304150-00001 · DOI · Paper page
  7. 10.2337/diacare.24.5.919 · DOI · Paper page
  8. 10.2337/diacare.21.1.104 · DOI · Paper page
  9. 10.1136/bmj.37970.629537.0D · DOI · Paper page
  10. 10.1016/S0002-9343(99)80226-5 · DOI · Paper page
  11. 10.2337/diacare.23.12.1823 · DOI · Paper page
  12. 10.1681/ASN.2007020256 · DOI
  13. 10.1161/01.CIR.0000146378.65439.7A · DOI · Paper page
  14. 10.1016/S0140-6736(96)11445-8 · DOI · Paper page
  15. 10.1056/NEJM199604113341502 · DOI · Paper page
  16. 10.1016/0895-7061(95)00162-I · DOI · Paper page
  17. 10.1016/j.jacc.2007.08.029 · DOI
  18. 10.1161/CIRCULATIONAHA.105.592733 · DOI · Paper page
  19. 10.7326/0003-4819-134-8-200104170-00007 · DOI · Paper page
  20. Strippoli GF, 2006, Cochrane Database Syst Rev, CD006257
  21. 10.2337/diacare.17.5.420 · DOI · Paper page
  22. 10.1161/CIRCULATIONAHA.110.964171 · DOI · Paper page
  23. 10.1016/S0140-6736(08)61236-2 · DOI · Paper page
  24. 10.1097/HJH.0b013e32830508aa · DOI · Paper page
  25. 10.1016/j.diabres.2005.06.010 · DOI
  26. 10.1046/j.1523-1755.2000.00224.x · DOI · Paper page
  27. 10.1681/ASN.2006121372 · DOI · Paper page
  28. 10.1161/CIRCULATIONAHA.109.853648 · DOI · Paper page
  29. 10.2215/CJN.01110905 · DOI
  30. 10.1016/j.cardfail.2008.11.003 · DOI
  31. 10.1093/eurjhf/hfp104 · DOI · Paper page
  32. 10.1161/CIRCHEARTFAILURE.109.932558 · DOI
  33. 10.1093/eurjhf/hfq038 · DOI
  34. 10.1001/archinte.158.12.1340 · DOI
  35. 10.1001/jama.288.19.2421 · DOI · Paper page
  36. 10.1038/ki.1995.361 · DOI · Paper page
  37. 10.1161/01.HYP.13.5_Suppl.I80 · DOI · Paper page
  38. 10.1016/S0140-6736(05)71082-5 · DOI · Paper page
  39. 10.1046/j.1523-1755.2002.00213.x · DOI · Paper page
  40. 10.1016/S0272-6386(99)70036-3 · DOI · Paper page
  41. 10.1056/NEJMoa0910975 · DOI · Paper page
  42. Ridker PM, 2010, J Am Coll Cardiol, 55, 1266, 10.1016/j.jacc.2010.01.020 · DOI · Paper page
  43. 10.1016/j.amjcard.2004.10.008 · DOI
  44. 10.1053/j.ajkd.2009.09.020 · DOI · Paper page
  45. 10.1016/j.atherosclerosis.2010.07.053 · DOI
  46. 10.1016/j.atherosclerosis.2009.03.031 · DOI
  47. 10.1053/j.ajkd.2008.05.027 · DOI
  48. 10.1161/01.CIR.0000143892.84582.60 · DOI · Paper page
  49. 10.1007/s00125-009-1467-8 · DOI · Paper page
  50. 10.1053/j.jrn.2005.07.003 · DOI · Paper page
  51. D'Amico G, 1994, Nephrol Dial Transplant, 9, 1590
  52. 10.1016/0140-6736(91)92977-A · DOI · Paper page
  53. Rosman JB, 1989, Kidney Int Suppl, 27, S96
  54. 10.1136/bmj.311.7011.973 · DOI · Paper page
  55. 10.2337/dc08-1908 · DOI · Paper page
  56. 10.1093/qjmed/hch039 · DOI
  57. 10.1016/S0002-9343(98)00329-5 · DOI
  58. 10.2215/CJN.07160810 · DOI
  59. 10.1016/j.amjmed.2007.05.012 · doi:10.1016/j.amjmed.2007.05.012
  60. 10.1053/ajkd.2003.50007 · DOI · Paper page
  61. 10.1056/NEJMoa021835 · DOI · Paper page
  62. 10.1053/j.ajkd.2009.11.017 · DOI
  63. 10.1001/jama.290.23.3101 · DOI · Paper page
  64. 10.1038/sj.ki.5001794 · DOI · Paper page
  65. 10.1097/01.ASN.0000091586.46532.B4 · DOI · Paper page
  66. 10.1038/sj.ki.5000058 · DOI · Paper page
  67. 10.1681/ASN.2010091001 · DOI · Paper page

Cited by

See all 154

Metadata

Authors
Fink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J.
Venue
Annals of Internal Medicine
Published
2012-04-17
Volume
156
Issue
8
Pages
570-581
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W4238687915
Cited by
154
References
25
FWCI
2.47
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. https://app.cochat.ai/papers/10.7326/0003-4819-156-8-201204170-00008
The paper
Fink, H. A., Ishani, A., Taylor, B. C., Greer, N. L., MacDonald, R., Rossini, D., Sadiq, S., Lankireddy, S., Kane, R. L., & Wilt, T. J. (2012). Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-8-201204170-00008

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.